tiprankstipranks
Trending News
More News >
Reflect Scientific (RSCF)
:RSCF
US Market
Advertisement

Reflect Scientific (RSCF) AI Stock Analysis

Compare
36 Followers

Top Page

RSCF

Reflect Scientific

(OTC:RSCF)

Rating:47Neutral
Price Target:
Reflect Scientific faces significant risks due to its weak financial performance, particularly in cash flow and profitability. However, the technical indicators suggest some short-term positive momentum. Valuation remains a concern with a negative P/E ratio, reflecting the company's current financial struggles.

Reflect Scientific (RSCF) vs. SPDR S&P 500 ETF (SPY)

Reflect Scientific Business Overview & Revenue Model

Company DescriptionReflect Scientific, Inc. (RSCF) is a technology company that specializes in providing innovative products and solutions primarily for the life sciences, biotechnology, pharmaceutical, and transportation industries. The company's core products include low-temperature freezers and refrigerated systems, which are critical for preserving biological samples and transporting temperature-sensitive goods. Reflect Scientific is dedicated to leveraging advanced technologies to improve the efficiency and reliability of cold storage solutions.
How the Company Makes MoneyReflect Scientific generates revenue primarily through the sale of its specialized refrigeration and cryogenic cooling systems. These products cater to a niche market that requires precise temperature control for research, storage, and transportation. Key revenue streams include direct sales to laboratories, pharmaceutical companies, and logistics firms that need to maintain the integrity of temperature-sensitive materials. In addition to product sales, Reflect Scientific may engage in strategic partnerships or collaborations with other companies in related sectors to enhance its offerings and expand its market reach. Service contracts and maintenance agreements for its equipment could also contribute to its revenue, ensuring recurring income from existing customers.

Reflect Scientific Financial Statement Overview

Summary
Reflect Scientific exhibits a mixed financial performance. The strong balance sheet with low leverage is offset by significant challenges in profitability and cash management, as highlighted by the income statement and cash flow issues.
Income Statement
45
Neutral
Reflect Scientific has seen significant fluctuations in its revenue and profitability. The TTM shows a noticeable increase in revenue from the previous year, but the company is still operating at a net loss. Gross profit margin remains relatively healthy at 40.1% for TTM, though net profit margin is negative, indicating potential issues in cost management or operational efficiency.
Balance Sheet
65
Positive
The company maintains a solid equity ratio of 88.9% and a low debt-to-equity ratio of 0.09, indicating strong financial stability and low leverage. However, a decline in total assets and stockholders' equity compared to previous years might suggest challenges in asset growth or capital retention.
Cash Flow
30
Negative
The cash flow situation is concerning, with negative operating and free cash flow in the TTM, reflecting potential liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating struggles in converting profits into cash.
BreakdownDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue1.08M2.04M2.81M2.79M1.61M
Gross Profit596.42K1.22M1.93M1.72M991.64K
EBITDA-405.78K146.32K996.22K723.35K-190.85K
Net Income-459.03K89.40K939.07K660.12K-196.34K
Balance Sheet
Total Assets2.67M2.45M2.48M1.68M1.08M
Cash, Cash Equivalents and Short-Term Investments1.28M1.38M1.47M642.54K555.16K
Total Debt242.64K57.39K113.84K279.36K67.61K
Total Liabilities776.33K149.59K299.24K463.31K525.75K
Stockholders Equity1.89M2.30M2.18M1.21M553.03K
Cash Flow
Free Cash Flow-103.98K-92.00K831.38K-25.22K335.87K
Operating Cash Flow-103.98K-92.00K831.38K-25.22K335.87K
Investing Cash Flow0.000.000.000.000.00
Financing Cash Flow0.002.25K27.50K112.60K-1.14K

Reflect Scientific Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.08
Price Trends
50DMA
0.06
Positive
100DMA
0.05
Positive
200DMA
0.05
Positive
Market Momentum
MACD
<0.01
Positive
RSI
50.57
Neutral
STOCH
64.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RSCF, the sentiment is Neutral. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.06, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 64.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RSCF.

Reflect Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$61.09M-1.01%28.29%87.42%
61
Neutral
$580.41M-7.77%48.42%-120.20%
52
Neutral
$7.60B0.11-62.95%2.07%16.16%0.31%
47
Neutral
$6.68M26.0012.92%25.64%88.89%
41
Neutral
$6.28M
3.53%52.86%
38
Underperform
$27.16M-1949.77%-89.76%80.28%
37
Underperform
$383.20K
-2.99%59.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RSCF
Reflect Scientific
0.07
0.02
40.00%
CYCC
Cyclacel Pharmaceuticals
16.04
-391.96
-96.07%
ICCC
Immucell
6.61
2.56
63.21%
AWHL
Aspira Women's Health
0.21
-1.28
-85.91%
AXDXQ
Accelerate Diagnostics
0.01
-1.29
-99.23%
ELTP
Elite Pharmaceuticals
0.55
0.36
189.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 30, 2025